Depression and risk of type 2 diabetes: the potential role of metabolic factors
This study looked at the interaction between depressive symptoms and metabolic dysregulations as risk factors for type II diabetes. The study found depressive symptoms and disruptions in metabolic regulation can lead to risk of type two diabetes.
Replication study of MATR3 in familial and sporadic amyotrophic lateral sclerosis
In this study, they looked at mutations of MATR3 (gene that is associated with ALS). They assessed the frequency in French Canadian populations and had a control group. They were able to determine which proteins are associated with ALS.
Comparison of the Effect of Thiazide Diuretics and Other Antihypertensive Drugs on Central Blood Pressure: Cross‐Sectional Analysis Among Nondiabetic Patients
This study used CARTaGENE data to determine to assess the noninferority of TDs relative to different classes of antihypertensive medications in relation to central blood pressure. No major differences were noted and it was shown that TDs are at least as effective as other first line medications that are available.
Association of age-dependent height and bone mineral density decline with increased arterial stiffness and rate of fractures in hypertensive individuals
They wanted to determine if there was an association with height, arterial stiffness, and bone fractures. They were able to determine at the end of the study that those with shorter statures were more likely to have arterial stiffness and hypertension.
Genetically encoded impairment of neuronal KCC2 cotransporter function in human idiopathic generalized epilepsy
These data describe a novel KCC2 variant significantly associated with a human disease and suggest genetically encoded impairment of KCC2 functional regulation may be a risk factor for the development of human IGE.
Pharmacogenomic data sample collection and storage: ethical issues and policy approaches
This journal highlighted that CARTaGENE’s data would become more important over time in pharmocogenomic research to find out the association between genetic variations and drug-related effects. The ability of database creators to meet ethical issues will determine how pharmocogenomics can be integrated into mainstream clinical practice.